409 EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with tralokinumab

Numerous targeted treatments for atopic dermatitis (AD) are currently under investigation in clinical trials. Comparability of the efficacy new drugs is therefore becoming more important. Serum biomarkers may offer an objective outcome measure disease severity AD. A combination serum TARC, IL-22, and sIL-2R as a signature (predicted EASI) measurement tool AD patients treated with topical steroids, cyclosporin A, or dupilumab. To validate predicted EASI (p-EASI) tralokinumab trial setting. samples were collected from 198 moderate to severe Phase 3 ECZTRA 1(NCT03131648) trial. Patients randomized (3:1) subcutaneous 300mg(n=149), placebo(n=49) every other week 16 weeks. Disease was assessed by EASI, at baseline after weeks treatment. measured Luminex. p-EASI scores highly correlated patients(r=.59, P<.0001). In tralokinumab, median decreased 30.9(IQR, 22.5-42.3) 32.9(IQR, 25.6-40.2), respectively, 13.5(IQR, 6.6-22.5) 24.8(IQR, 20.6-59.0) placebo group, 31.1 (IQR, 22.5-40.4) 31.3(IQR, 25.0-37.5), baseline; 19.0(IQR, 10.2-29.1) 29.2(IQR, 25.5-32.5) These findings suggest that better reflect accurate effects The biomarker moderate-severe use such be considered objectively assess treatment effect